

March 31, 2025

Sixty-ninth  
Legislative Assembly  
of North Dakota

**PROPOSED AMENDMENTS TO  
FIRST ENGROSSMENT**

**ENGROSSED HOUSE BILL NO. 1203**

Introduced by

Representatives Vetter, Dobervich, M. Ruby, Steiner, Frelich, Christianson, Christy, Bahl

Senators Cory, Meyer

1 A BILL for an Act to create and enact section 19-24.1-24.1 and a new subsection to section  
2 19-24.1-36 of the North Dakota Century Code, relating to regulating edible medical marijuana  
3 products; and to amend and reenact section 19-24.1-01 of the North Dakota Century Code,  
4 relating to definitions of medical marijuana products.

5 **BE IT ENACTED BY THE LEGISLATIVE ASSEMBLY OF NORTH DAKOTA:**

6 **SECTION 1. AMENDMENT.** Section 19-24.1-01 of the North Dakota Century Code is  
7 amended and reenacted as follows:

8 **19-24.1-01. Definitions.**

9 As used in this chapter, unless the context indicates otherwise:

- 10 1. "Advanced practice registered nurse" means an advanced practice registered nurse  
11 defined under section 43-12.1-02.
- 12 2. "Agent" means an individual who is authorized to act for, in place of, or on behalf of a  
13 compassion center.
- 14 3. "Allowable amount of usable marijuana" means the amount of usable marijuana a  
15 registered qualifying patient or registered designated caregiver may purchase in a  
16 thirty-day period under this chapter.
- 17 a. Except as provided under subdivision b:
- 18 (1) During a thirty-day period, a registered qualifying patient may not purchase  
19 or have purchased by a registered designated caregiver more than two and

one-half ounces [70.87 grams] of dried leaves or flowers of the plant of the genus cannabis in a combustible delivery form.

(2) At any time a registered qualifying patient, or a registered designated caregiver on behalf of a registered qualifying patient, may not possess more than three ounces [85.05 grams] of dried leaves or flowers of the plant of the genus cannabis in a combustible delivery form.

(3) At any time, a registered qualifying patient, or a registered designated caregiver on behalf of a registered qualifying patient, may not possess more than five hundred milligrams of a cannabinoid edible product.

b. Notwithstanding subdivision a, if a registered qualifying patient has a registry identification card authorizing an enhanced allowable amount:

(1) During a thirty-day period a registered qualifying patient may not purchase or have purchased by a registered designated caregiver more than six ounces [170.01 grams] of dried leaves or flowers of the plant of genus cannabis in a combustible delivery form.

(2) At any time a registered qualifying patient, or a registered designated caregiver on behalf of a registered qualifying patient, may not possess more than seven and one-half ounces [212.62 grams] of dried leaves or flowers of the plant of the genus cannabis in a combustible delivery form.

(3) At any time, a registered qualifying patient, or a registered designated caregiver on behalf of a registered qualifying patient, may not possess more than five hundred milligrams of a cannabinoid edible product.

c. A registered qualifying patient may not purchase or have purchased by a registered designated caregiver more than the maximum concentration or amount of tetrahydrocannabinol permitted in a thirty-day period. The maximum concentration or amount of tetrahydrocannabinol permitted in a thirty-day period for a cannabinoid concentrate or medical cannabinoid product, or the cumulative total of both, is six thousand milligrams. At any time, a registered qualifying patient, or a registered designated caregiver on behalf of a registered qualifying patient, may not purchase more than three hundred ten milligrams of tetrahydrocannabinol in the form of a cannabinoid edible product.

- 1        4. "Bona fide provider-patient relationship" means a treatment or counseling relationship  
2        between a health care provider and patient in which all the following are present:
- 3        a. The health care provider has reviewed the patient's relevant medical records and  
4        completed a full assessment of the patient's medical history and current medical  
5        condition, including a relevant, ~~in-person~~, medical evaluation of the patient.
- 6        b. The health care provider has created and maintained records of the patient's  
7        condition in accordance with medically accepted standards.
- 8        c. The patient is under the health care provider's continued care for the debilitating  
9        medical condition that qualifies the patient for the medical use of marijuana.
- 10       d. The health care provider has a reasonable expectation that provider will continue  
11       to provide followup care to the patient to monitor the medical use of marijuana as  
12       a treatment of the patient's debilitating medical condition.
- 13       e. The relationship is not for the sole purpose of providing written certification for the  
14       medical use of marijuana.
- 15       5. "Cannabinoid" means a chemical compound that is one of the active constituents of  
16       marijuana.
- 17       6. "Cannabinoid capsule" means a small, soluble container, usually made of gelatin,  
18       which encloses a dose of a cannabinoid product or a cannabinoid concentrate  
19       intended for consumption. The maximum concentration of amount of  
20       tetrahydrocannabinol permitted in a serving of a cannabinoid capsule is fifty  
21       milligrams.
- 22       7. "Cannabinoid concentrate" means a concentrate or extract obtained by separating  
23       cannabinoids from marijuana by a mechanical, chemical, or other process.
- 24       8. "Cannabinoid edible product" means a ~~feed or potable liquid~~ soft or hard lozenge in a  
25       geometric square shape into which a cannabinoid concentrate or the dried leaves or  
26       flowers of the plant of the genus cannabis is incorporated.
- 27       a. The maximum concentration or amount of tetrahydrocannabinol permitted in a  
28       serving of a cannabinoid edible product is ~~ten~~five milligrams and in a package is  
29       fifty milligrams.
- 30       b. The term does not include a hard or soft lozenge in a geometric square shape  
31       into which a cannabinoid concentrate or the dried leaves or flowers of the plant of

1                   the genus cannabis is incorporated if the form, packaging, or labeling is target  
2                   marketed to minors.

3           9.   "Cannabinoid solution" means a solution consisting of a mixture created from  
4           cannabinoid concentrate and other ingredients. A container holding a cannabinoid  
5           solution for dispensing may not exceed thirty milliliters.

6           10. "Cannabinoid topical" means a cannabinoid product intended to be applied to the skin  
7           or hair. The maximum concentration or amount of tetrahydrocannabinol permitted in a  
8           cannabinoid topical is six percent.

9           11. "Cannabinoid transdermal patch" means an adhesive substance applied to the skin  
10          which contains a cannabinoid product or cannabinoid concentrate for absorption into  
11          the bloodstream. The maximum concentration or amount of tetrahydrocannabinol  
12          permitted in a serving of a cannabinoid transdermal patch is fifty milligrams.

13          12. "Cardholder" means a qualifying patient, designated caregiver, or compassion center  
14          agent who has been issued and possesses a valid registry identification card.

15          13. "Compassion center" means a manufacturing facility or dispensary.

16          14. "Compassion center agent" means a principal officer, board member, member,  
17          manager, governor, employee, volunteer, or agent of a compassion center. The term  
18          does not include a lawyer representing a compassion center in civil or criminal  
19          litigation or in an adversarial administrative proceeding.

20          15. "Contaminated" means made impure or inferior by extraneous substances.

21          16. "Debilitating medical condition" means one of the following:

- 22           a.   Cancer;
- 23           b.   Positive status for human immunodeficiency virus;
- 24           c.   Acquired immune deficiency syndrome;
- 25           d.   Decompensated cirrhosis caused by hepatitis C;
- 26           e.   Amyotrophic lateral sclerosis;
- 27           f.   Posttraumatic stress disorder;
- 28           g.   Agitation of Alzheimer's disease or related dementia;
- 29           h.   Crohn's disease;
- 30           i.   Fibromyalgia;

- 1           j.    Spinal stenosis or chronic back pain, including neuropathy or damage to the  
2                nervous tissue of the spinal cord with objective neurological indication of  
3                intractable spasticity;  
4           k.    Glaucoma;  
5           l.    Epilepsy;  
6           m.    Anorexia nervosa;  
7           n.    Bulimia nervosa;  
8           o.    Anxiety disorder;  
9           p.    Tourette syndrome;  
10          q.    Ehlers-Danlos syndrome;  
11          r.    Endometriosis;  
12          s.    Interstitial cystitis;  
13          t.    Neuropathy;  
14          u.    Migraine;  
15          v.    Rheumatoid arthritis;  
16          w.    Autism spectrum disorder;  
17          x.    A brain injury;  
18          y.    A terminal illness; or  
19          z.    A chronic or debilitating disease or medical condition or treatment for such  
20                disease or medical condition that produces one or more of the following:  
21                (1)   Cachexia or wasting syndrome;  
22                (2)   Severe debilitating pain that has not responded to previously prescribed  
23                      medication or surgical measures for more than three months or for which  
24                      other treatment options produced serious side effects;  
25                (3)   Intractable nausea;  
26                (4)   Seizures; or  
27                (5)   Severe and persistent muscle spasms, including those characteristic of  
28                      multiple sclerosis.  
29       17.    "Department" means the department of health and human services.

- 1       18. "Designated caregiver" means an individual who agrees to manage the well-being of a  
2       registered qualifying patient with respect to the qualifying patient's medical use of  
3       marijuana.
- 4       19. "Dispensary" means an entity registered by the department as a compassion center  
5       authorized to dispense usable marijuana to a registered qualifying patient and a  
6       registered designated caregiver.
- 7       20. "Enclosed, locked facility" means a closet, room, greenhouse, building, or other  
8       enclosed area equipped with locks or other security devices that permit access limited  
9       to individuals authorized under this chapter or rules adopted under this chapter.
- 10      21. "Health care provider" means a physician, a physician assistant, or an advanced  
11      practice registered nurse.
- 12      22. "Manager" means an individual who administers or supervises the day-to-day  
13      operations and affairs of a compassion center.
- 14      23. "Manufacturing facility" means an entity registered by the department as a compassion  
15      center authorized to produce and process and to sell usable marijuana to a  
16      dispensary.
- 17      24. "Marijuana" means all parts of the plant of the genus cannabis; the seeds of the plant;  
18      the resin extracted from any part of the plant; and every compound, manufacture, salt,  
19      derivative, mixture, or preparation of the plant, the seeds of the plant, or the resin  
20      extracted from any part of the plant. The term marijuana does not include:  
21      a. Hemp as regulated under section 4.1-18.1-01; or  
22      b. A prescription drug approved by the United States food and drug administration  
23      under section 505 of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355].
- 24      25. "Maximum concentration or amount of tetrahydrocannabinol" means the total amount  
25      of tetrahydrocannabinol and tetrahydrocannabinolic acid in a medical cannabinoid  
26      product or a cannabinoid concentrate.
- 27      26. "Medical cannabinoid product" means a product intended for human consumption or  
28      use which contains cannabinoids.  
29      a. Medical cannabinoid products are limited to the following forms:  
30          (1) Cannabinoid solution;  
31          (2) Cannabinoid capsule;

1                   (3) Cannabinoid transdermal patch; and

2                   (4) Cannabinoid topical; and

3                   (5) Cannabinoid edible products.

4           b. "Medical cannabinoid product" does not include:

5                   (1) ~~A cannabinoid edible product;~~

6                   ~~(2)~~ A cannabinoid concentrate by itself; or

7                   ~~(3)~~(2) The dried leaves or flowers of the plant of the genus cannabis by itself.

8       27. "Medical marijuana product" means a cannabinoid concentrate or a medical  
9       cannabinoid product.

10      28. "Medical marijuana waste" means unused, surplus, returned, or out-of-date usable  
11      marijuana; recalled usable marijuana; unused marijuana; or plant debris of the plant of  
12      the genus cannabis, including dead plants and all unused plant parts and roots.

13      29. "Medical use of marijuana" means the acquisition, use, and possession of usable  
14      marijuana to treat or alleviate a qualifying patient's debilitating medical condition.

15      30. "Member" means an individual who has a ten percent or more ownership interest in  
16      the compassion center limited liability company, limited liability partnership, or  
17      partnership.

18      31. "Minor" means an individual under the age of nineteen.

19      32. "North Dakota identification" means a North Dakota driver's license or comparable  
20      state of North Dakota or federal issued photo identification card verifying North Dakota  
21      residence.

22      33. "Owner" means an individual or an organization with an ownership interest in a  
23      compassion center.

24      34. "Ownership interest" means an aggregate ownership interest of five percent or more in  
25      a compassion center, unless the interest is solely a security, lien, or encumbrance, or  
26      an individual who will be participating in the direction, control, or management of the  
27      compassion center.

28      35. "Pediatric medical marijuana" means a medical marijuana product containing  
29      cannabidiol which may not contain a maximum concentration or amount of  
30      tetrahydrocannabinol of more than six percent.

- 1       36. "Physician" means a physician licensed under chapter 43-17 to practice medicine in  
2       the state of North Dakota.
- 3       37. "Physician assistant" means an individual licensed under chapter 43-17 to practice as  
4       a physician assistant in the state.
- 5       38. "Posttraumatic stress disorder" means a patient meets the diagnostic criteria for  
6       posttraumatic stress disorder under the "Diagnostic and Statistical Manual of Mental  
7       Disorders", American psychiatric association, fifth edition, text revision (2013).
- 8       39. "Processing" or "process" means the compounding or conversion of marijuana into a  
9       medical marijuana product.
- 10      40. "Producing", "produce", or "production" mean the planting, cultivating, growing,  
11      trimming, or harvesting of the plant of the genus cannabis or the drying of the leaves  
12      or flowers of the plant of the genus cannabis.
- 13      41. "Qualifying patient" means an individual who has been diagnosed by a health care  
14      provider as having a debilitating medical condition.
- 15      42. "Registry identification card" means a document issued by the department which  
16      identifies an individual as a registered qualifying patient, registered designated  
17      caregiver, or registered compassion center agent.
- 18      43. "Substantial corporate change" means:
- 19          a. For a corporation, a change of ten percent or more of the officers or directors, or  
20          a transfer of ten percent or more of the stock of the corporation, or an existing  
21          stockholder obtaining ten percent or more of the stock of the corporation;
- 22          b. For a limited liability company, a change of ten percent or more of the managing  
23          members of the company, or a transfer of ten percent or more of the ownership  
24          interest in the company, or an existing member obtaining a cumulative of ten  
25          percent or more of the ownership interest in the company; or
- 26          c. For a partnership, a change of ten percent or more of the managing partners of  
27          the company, or a transfer of ten percent or more of the ownership interest in the  
28          company, or an existing member obtaining a cumulative of ten percent or more of  
29          the ownership interest in the company.
- 30      44. "Terminal illness" means a disease, illness, or condition of a patient:
- 31          a. For which there is not a reasonable medical expectation of recovery;



- 1           b. Which as a medical probability, will result in the death of the patient, regardless of  
2           the use or discontinuance of medical treatment implemented for the purpose of  
3           sustaining life or the life processes; and  
4           c. As a result of which, the patient's health care provider would not be surprised if  
5           death were to occur within six months.

6       45. "Tetrahydrocannabinol" means tetrahydrocannabinols naturally contained in a plant of  
7       the genus cannabis, and synthetic equivalents of the substances contained in the  
8       cannabis plant, or in the resinous extractives of the plant, including synthetic  
9       substances, derivatives, and their isomers with similar chemical structure and  
10      pharmacological activity to those substances contained in the plant, including:

- 11      a. (1) Delta-1 cis or trans tetrahydrocannabinol, and their optical isomers. Other  
12          names: Delta-9-tetrahydrocannabinol.  
13          (2) Delta-6 or trans tetrahydrocannabinol, and their optical isomers. Other  
14          names: Delta-8 tetrahydrocannabinol.  
15          (3) Delta-3, 4 cis or trans tetrahydrocannabinol, and its optical isomers.

16      (Since nomenclature of these substances is not intentionally standardized, compounds  
17      of these structures, regardless of numerical designation or atomic positions covered.)

18      b. Tetrahydrocannabinol does not include:

- 19          (1) The allowable amount of total tetrahydrocannabinol found in hemp as  
20          defined in chapter 4.1-18.1; or  
21          (2) A prescription drug approved by the United States food and drug  
22          administration under section 505 of the Federal Food, Drug, and Cosmetic  
23          Act [21 U.S.C. 355].

24      46. "Total tetrahydrocannabinol" means the sum of the percentage by weight of  
25      tetrahydrocannabinolic acid multiplied by eight hundred seventy-seven thousandths  
26      plus the percentage of weight of tetrahydrocannabinol.

27      47. "Usable marijuana" means a medical marijuana product or the dried leaves or flowers  
28      of the plant of the genus cannabis in a combustible delivery form. ~~However, the term~~  
29      ~~does not include a cannabinoid edible product.~~ In the case of a registered qualifying  
30      patient who is a minor, "usable marijuana" is limited to pediatric medical marijuana.

1       48. "Verification system" means the system maintained by the department under section  
2       19-24.1-31 for verification of registry identification cards.

3       49. "Written certification" means a form established by the department which is executed,  
4       dated, and signed by a health care provider within ninety calendar days of the date of  
5       application, stating the patient has a debilitating medical condition. A health care  
6       provider may authorize an enhanced amount of dried leaves or flowers of the plant of  
7       the genus cannabis in a combustible delivery form to treat or alleviate the patient's  
8       debilitating medical condition of cancer. A written certification may not be made except  
9       in the course of a bona fide provider-patient relationship.

10       **SECTION 2.** Section 19-24.1-24.1 of the North Dakota Century Code is created and  
11       enacted as follows:

12       **19-24.1-24.1. Compassion centers - Cannabinoid edible products.**

- 13       1. A manufacturing facility may not manufacture a cannabinoid edible product unless the  
14       manufacturing facility has received the prior approval of the department.
- 15       2. A dispensary may not possess, market, or sell a cannabinoid edible product unless the  
16       dispensary has received the prior approval of the department.
- 17       3. The department may not approve the manufacturing, possession, marketing, or sale of  
18       a cannabinoid edible product unless the department has reviewed and approved the  
19       form, manufacturing, packaging, labeling, and marketing of the cannabinoid edible  
20       product.
- 21       a. Packaging of a cannabinoid edible product must be resealable, must be child  
22       resistant, and may not be transparent. The maximum concentration or amount of  
23       tetrahydrocannabinol permitted in a package is ~~one hundred~~fifty milligrams.
- 24       b. Labeling of a cannabinoid edible product must be in black arial font which  
25       provides the name of the product, manufacturer's information, ingredient list,  
26       milligrams of tetrahydrocannabinol per serving, and number of servings per  
27       package. The labeling may not include an image other than text.
- 28       c. Marketing may not target market to minors.

29       **SECTION 3.** A new subsection to section 19-24.1-36 of the North Dakota Century Code is  
30       created and enacted as follows:

- 1           The department shall adopt rules to regulate the form, manufacturing, packaging,
- 2           labeling, and marketing of a cannabinoid edible product. The rules must prohibit the
- 3           marketing of a cannabinoid edible product to a minor.